TNFSF10 and breast carcinoma: Previous research testing the effects of US with TRAIL has developed co‐encapsulation of doxorubicin and TRAIL in US‐responsive microbubbles to enhance apoptosis, which would still require the need for complex vehicle construction.[32] US‐targeted microbubble destruction has also been shown to reverse the epithelial to mesenchymal transition (EMT) in breast cancer cells, thereby reducing metastatic ability.[33] The combined use of US contrast agents with taurolidine, TRAIL and US exposure has also been explored; however, this therapy has not yet been tested in vivo.[34]